Condition: Systemic Lupus Erythematosus (SLE) · Refractory · Sponsor: Chongqing Precision Biotech Co., Ltd
This is a single-arm, open, dose-increasing and dose-expanding phase I clinical trial to investigate the safety, tolerability and cytodynamic characteristics of MC-1-50 cell preparation, and to preliminatively observe the efficacy of MC-1-50 cell preparation in patients with refractory SLE, and to explore the applicable dose regimen for phase II clinical trials.
This description comes directly from the study's public registry record.
Jing Xue, M.D. · +8613858121751 · xuej@zju.edu.cn
Zhu Chen, M.D. · +8613956963042 · doczchen@gmail.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) | Hefei, Anhui, China | Recruiting |
| The Second Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06892145